StreetInsider.com News Articles

Bio-Techne and Refeyn launch integrated workflow for antibody analysis

Thu, 04 Jun 2026 06:31:05 -0400

Bio-Techne Corporation (NASDAQ: TECH) and Refeyn announced a new integrated workflow that combines imaged capillary isoelectric focusing fractionation with mass photometry technology for analyzing bispecific antibodies and biosimilars.

The workflow integrates Bio-Techne's R&D Systems MauriceFlex imaged capillary isoelectric focusing system with Refeyn's TwoMP mass photometry platform. The combination allows researchers to analyze charge heterogeneity alongside molecular weight and aggregation at single-molecule resolution in a four-hour process.

The MauriceFlex system separates and fractionates charge variants, while the TwoMP platform analyzes size distribution and aggregation using nanogram-level samples. The workflow enables direct characterization of aggregation and size within charge variants that were previously separated

Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization

Thu, 04 Jun 2026 06:30:00 -0400

New integrated workflow combines icIEF fractionation and mass photometry
Enables direct characterization of aggregation and size within icIEF-resolved charge variants
Four-hour workflow reduces development risk and accelerates biosimilar manufacturing

MINNEAPOLIS and OXFORD, England, June 4, 2026 /PRNewswire/ -- Bio‑Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first‑of‑its‑kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars.

By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system

Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization

Thu, 04 Jun 2026 06:30:00 -0400

New integrated workflow combines icIEF fractionation and mass photometry
Enables direct characterization of aggregation and size within icIEF-resolved charge variants
Four-hour workflow reduces development risk and accelerates biosimilar manufacturing

By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system

Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization

Thu, 04 Jun 2026 06:30:00 -0400

New integrated workflow combines icIEF fractionation and mass photometry
Enables direct characterization of aggregation and size within icIEF-resolved charge variants
Four-hour workflow reduces development risk and accelerates biosimilar manufacturing

By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system

Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization

Thu, 04 Jun 2026 06:30:00 -0400

New integrated workflow combines icIEF fractionation and mass photometry
Enables direct characterization of aggregation and size within icIEF-resolved charge variants
Four-hour workflow reduces development risk and accelerates biosimilar manufacturing

By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system

Form SD BIO-TECHNE Corp

Mon, 01 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260601/26584239.html

Form SD BIO-TECHNE Corp

Mon, 01 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260601/26584239.html

RBC Capital Assumes Bio-Techne Corp. (TECH) at Outperform

Thu, 14 May 2026 16:27:41 -0400

(Updated - May 14, 2026 4:27 PM EDT)

RBC Capital analyst Dan Leonard assumes coverage on Bio-Techne Corp. (NASDAQ: TECH) with a Outperform rating and a price target of $62.00.

The analyst comments "We resume coverage of Bio-Techne (TECH) with an Outperform rating and $62 price target, which reflects our confidence that sales growth will rebound and company's planned acquisition of Wilson Wolf is underappreciated. Bio-Techne is the most levered to the improved biotech funding environment in our coverage. While waiting for the market rebound, the company is not sitting still, but rather executing on multiple initiatives to improve its business mix

RBC Capital Assumes Bio-Techne Corp. (TECH) at Outperform

Thu, 14 May 2026 16:27:41 -0400

(Updated - May 14, 2026 4:27 PM EDT)

RBC Capital analyst Dan Leonard assumes coverage on Bio-Techne Corp. (NASDAQ: TECH) with a Outperform rating and a price target of $62.00.

Form 4 BIO-TECHNE Corp For: May 08 Filed by: Herr Amy E.

Tue, 12 May 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260512/26477538.html

Form 4 BIO-TECHNE Corp For: May 08 Filed by: Herr Amy E.

Tue, 12 May 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260512/26477538.html

Form 144 BIO-TECHNE Corp Filed by: Herr Amy E.

Fri, 08 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260508/26461503.html

Form 144 BIO-TECHNE Corp Filed by: Herr Amy E.

Fri, 08 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260508/26461503.html

Form 4 BIO-TECHNE Corp For: May 05 Filed by: Hippel James

Thu, 07 May 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260507/26455352.html

Form 4 BIO-TECHNE Corp For: May 05 Filed by: Hippel James

Thu, 07 May 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260507/26455352.html

Form 4 BIO-TECHNE Corp For: May 05 Filed by: Bohnen Shane

Thu, 07 May 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260507/26455332.html

Form 4 BIO-TECHNE Corp For: May 05 Filed by: Bohnen Shane

Thu, 07 May 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260507/26455332.html

Form 4 BIO-TECHNE Corp For: May 05 Filed by: Kelderman Kim

Thu, 07 May 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260507/26455303.html

Form 4 BIO-TECHNE Corp For: May 05 Filed by: Kelderman Kim

Thu, 07 May 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260507/26455303.html

Bio-Techne Corp. (TECH) PT Lowered to $62 at Wells Fargo

Thu, 07 May 2026 08:25:05 -0400

Wells Fargo analyst Brandon Couillard lowered the price target on Bio-Techne Corp. (NASDAQ: TECH) to $62.00 (from $76.00) while maintaining a Overweight rating.

Bio-Techne Corp. (TECH) PT Lowered to $50 at Stifel

Thu, 07 May 2026 07:30:32 -0400

Stifel analyst Daniel Arias lowered the price target on Bio-Techne Corp. (NASDAQ: TECH) to $50.00 (from $65.00) while maintaining a Hold rating.

Bio-Techne Corp. (TECH) PT Lowered to $49 at Baird

Thu, 07 May 2026 07:11:15 -0400

Baird analyst Catherine Schulte lowered the price target on Bio-Techne Corp. (NASDAQ: TECH) to $49.00 (from $70.00) while maintaining a Neutral rating.

Form 10-Q BIO-TECHNE Corp For: Mar 31

Wed, 06 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260506/26444673.html

Form 10-Q BIO-TECHNE Corp For: Mar 31

Wed, 06 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260506/26444673.html

Form SCHEDULE 13G BIO-TECHNE Corp Filed by: FMR LLC

Wed, 06 May 2026 11:01:00 -0400

si-local-file:///var/storage/secattach/20260506/26441285.html